A Multicenter Phase II Trial of Carboplatin and Cetuximab for Treatment of Advanced Nonsmall Cell Lung Cancer

ABSTRACT Purpose: To investigate the activity of carboplatin and cetuximab in NSCLC. Patients and Methods: This was a single arm, multicenter phase II trial, and the primary objective was response rate. Results: The overall response rate observed was 9% (95% confidence interval [CI], 3-19), the prog...

Full description

Saved in:
Bibliographic Details
Published in:Cancer investigation 2010-02, Vol.28 (2), p.208-215
Main Authors: Stinchcombe, Thomas E., Bradford, Daniel S., Hensing, Thomas A., LaRocca, Renato V., Saleh, Mansoor, Evans, Tracey, Bakri, Kamal, Socinski, Mark A.
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carboplatin - administration & dosage
Carcinoma, Non-Small-Cell Lung - drug therapy
Cetuximab
Clinical trial
Epidermal growth factor receptor (EGFR)
Female
First-line therapy
Humans
Lung cancer
Lung Neoplasms - drug therapy
Male
Middle Aged
Platinum-based
Survival Analysis
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Purpose: To investigate the activity of carboplatin and cetuximab in NSCLC. Patients and Methods: This was a single arm, multicenter phase II trial, and the primary objective was response rate. Results: The overall response rate observed was 9% (95% confidence interval [CI], 3-19), the progression-free survival was 2.9 months (95% CI, 1.9-3.6), the median overall survival was 8.2 months (95% CI, 4.9-10.5), and 1-year survival rate was 33% (95% CI, 21-45). Conclusion: The combination of carboplatin and cetuximab demonstrated lower activity than double agent platinum-based therapy and does not warrant further development.
ISSN:0735-7907
1532-4192
DOI:10.3109/07357900903286958